ctDNA MRD detection from plasma and urine in colorectal cancer

• Date : 10/04/2021
• 16    
  0

Evolution of genomic tools shaping treatment decision making in breast cancer

• Date : 10/04/2021
• 13    
  0

Chromosomal instability as a therapeutic target

• Date : 10/04/2021
• 4    
  0

Upcoming advances in prostate cancer: PARPi, CDK4/6, lutetium PSMA therapy & CAR-T approaches

• Date : 10/04/2021
• 1    
  0

Single-cell transcriptomics in liver cancer

• Date : 10/04/2021
• 1    
  0

IMbrave150: updated data on atezo plus bev versus sorafenib in HCC

• Date : 10/04/2021
• 1    
  0

Chromosomal instability and tumor evolution

• Date : 10/04/2021
• 1    
  0

Diversifying populations represented in cancer genomics

• Date : 10/04/2021
• 1    
  0

Current activites at Transgene

• Date : 10/04/2021
• 0    
  0

DFIR CAR T-cell therapy for clear cell RCC

• Date : 10/04/2021
• 0    
  0

TREM2 targeting TAMs for ICI-resistant tumors

• Date : 10/04/2021
• 0    
  0

Using oncolytic viruses in solid tumors

• Date : 10/04/2021
• 0    
  0

Impact of the TME on CAR T-cell therapy for kidney cancer

• Date : 10/04/2021
• 0    
  0

Heritability of cancer predisposition gene mutations in neuroblastoma

• Date : 10/04/2021
• 0    
  0

TG6002, an oncolytic virus induces expression of a pro-drug activating enzyme in advanced GI cancers

• Date : 10/04/2021
• 0    
  0

Highlights from AACR 2021

• Date : 10/04/2021
• 0    
  0

ZENITH20-5: poziotinib for EGFR/HER2 exon 20 mutant NSCLC

• Date : 10/04/2021
• 0    
  0

Combining EGFR and VEGF inhibitors for NSCLC

• Date : 10/04/2021
• 0    
  0

Harnessing the value of mutational signatures in whole cancer genomes

• Date : 10/04/2021
• 0    
  0

Oleclumab plus osimertinib for advanced EGFRm NSCLC

• Date : 10/04/2021
• 0    
  0

Tumor methionine metabolism drives T-cell exhaustion in HCC

• Date : 10/04/2021
• 0    
  0

Optimizing gemcitabine in metastatic TNBC

• Date : 10/04/2021
• 0    
  0

Overcoming resistance to PARPi in BRCA1-deficient breast cancer with STING agonists

• Date : 10/04/2021
• 0    
  0

Wil FAPI PET/CT replace FDG PET/CT in the next decade?

• Date : 10/04/2021
• 0    
  0

Validation of FAPi PET biodistribution

• Date : 10/04/2021
• 0    
  0

Clinical utility of liquid biopsies in prostate cancer

• Date : 10/04/2021
• 0    
  0

Treating ER+ breast cancer patients with endocrine therapy resistance

• Date : 10/04/2021
• 0    
  0

Endocrine therapy resistance in ER+ metastatic breast cancer

• Date : 10/04/2021
• 0    
  0

RAMP: Phase Ib study of rucaparib & enzalutamide in mCRPC

• Date : 10/04/2021
• 0    
  0

Analysis and comparison of PD-L1 IHC tests

• Date : 10/04/2021
• 0    
  0

Optimal application of PD-L1 IHC tests

• Date : 10/04/2021
• 0    
  0

DNA MRD markers in pediatric solid cancers

• Date : 10/04/2021
• 0    
  0

ctDNA and cfDNA : prognostic value in the neoadjuvant setting of colon cancer

• Date : 10/04/2021
• 0    
  0

Areas of unmet need for patients with advanced UC

• Date : 10/04/2021
• 0    
  0

Molecular profiling of exceptional responders to cancer therapy

• Date : 10/04/2021
• 0    
  0

IMvigor130: OS data for atezolizumab plus chemo versus chemo alone

• Date : 10/04/2021
• 0    
  0

Key findings on atezolizumab for mUC from IMvigor130

• Date : 10/04/2021
• 0    
  0

CANOPY-A: canakinumab for resected NSCLC

• Date : 10/04/2021
• 0    
  0

Mobocertinib for previously treated NSCLC with EFGR mutations

• Date : 10/04/2021
• 0    
  0

Modernization of clinical trial eligibility criteria

• Date : 10/04/2021
• 0    
  0

Future approaches to treating colorectal cancer

• Date : 10/04/2021
• 0    
  0

CAR-T for Ewing’s sarcoma: impacts of the tumor microenvironment

• Date : 10/04/2021
• 0    
  0

Future treatment landscape for sarcoma

• Date : 10/04/2021
• 0    
  0

FGFR-4-targeted CARs for rhabdomyosarcoma

• Date : 10/04/2021
• 0    
  0

Combining genetic and cell biology research

• Date : 10/04/2021
• 0    
  0

CROWN: biomarkers for lorlatinib response in patients with ALK+ NSCLC

• Date : 10/04/2021
• 0    
  0

REGINA: regorafenib, nivolumab and short-course radiotherapy for rectal cancer

• Date : 10/04/2021
• 0    
  0

Future targets for pancreatic cancer treatment

• Date : 10/04/2021
• 0    
  0

Mutant p53 and oncogenic KRAS drive metastasis in pancreatic cancer

• Date : 10/04/2021
• 0    
  0

Future treatment landscape for colon cancer

• Date : 10/04/2021
• 0    
  0

Enhancing cell-free DNA mutation detection with novel liquid-phase extraction

• Date : 10/04/2021
• 0    
  0

Survival for patients with early-onset CRC

• Date : 10/04/2021
• 0    
  0

HAMMER: THOR-707, a novel not-alpha IL-2 in advanced/metastatic solid tumors

• Date : 10/04/2021
• 0    
  0

KEYNOTE-555: pembrolizumab bioavailability after subcutaneous administration in melanoma

• Date : 10/04/2021
• 0    
  0

Racial differences in somatic mutations among patients with early-onset CRC

• Date : 10/04/2021
• 0    
  0

First-in-human trial of intratumoral injection of SYNB1891

• Date : 10/04/2021
• 0    
  0

NADIM: baseline ctDNA as a prognostic factor for PFS

• Date : 10/04/2021
• 0    
  0

Guadecitabine + atezolizumab in mUC who have progressed after initial checkpoint inhibitor therapy

• Date : 10/04/2021
• 0    
  0

Congrès ESMO 2026

• Date : 23/10/2026
• 3970    
  0

Congrès ESMO d'Immuno-Oncologie 2025

• Date : 10/12/2025
• 4712    
  0

SABCS 2025 Symposium

• Date : 09/12/2025
• 13131    
  0

Congrès ESMO Asie 2025

• Date : 05/12/2025
• 3392    
  0

17ᵉ Congrès Européen Multidisciplinaire sur le Cancer Urologique - EMUC25

• Date : 13/11/2025
• 3521    
  0